Yissum - Research Development Company of the Hebrew University

Naturally Occurring Compounds for Treating Pathogenic Factors Common to Cystic Fibrosis

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cannabis project
Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF

Project ID : 6-2019-6720

Description of the technology

Cystic Fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. There is no known cure for cystic fibrosis and the average life expectancy is between 42 and 50 years in the developed world. Lung problems are responsible for death in 80% of people with CF.
Our Invention suggests a novel regime of treatment using naturally occurring compounds with little side effects, to fight pathogenic factors common to CF, affecting the microbial biofilm in the lungs and reducing the need of antibiotics/antifungal drugs.
Specifically, the anti-bacterial, anti-fungal anti-biofilm effects on Candida albicans and Pseudomonas aeruginosa, both common to CF patients, is demonstrated.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Doron Steinberg
HUJI, Faculty of Dental Medicine
Institute of Dental Sciences

Related keywords

  • Applications for Health
  • Medicine, Human Health
  • Clinical Research, Trials
  • Diagnostics, Diagnosis
  • Medical Research
  • Medical Technology / Biomedical Engineering
  • Stem cell Technologies
  • Medical Biomaterials
  • Genetic Engineering Technology
  • Biological Sciences
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Biochemistry / Biophysics Technology
  • Medical Health related
  • Therapeutic
  • Therapeutic services
  • Medical/health
  • Industrial genetic engineering applications
  • Genetic Engineering / Molecular Biology
  • Monoclonal Antibodies and Hybridomas
  • Micro- and Nanotechnology related to Biological sciences

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.